Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 07 Apr 2017 Planned End Date changed from 1 Jan 2018 to 13 Jul 2018.
- 07 Apr 2017 Planned primary completion date changed from 1 Jan 2018 to 13 Jul 2018.
- 31 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 Jan 2018.